Thursday, 15 July 2010

A new era of Multiple Sclerosis therapies begins

From the MSRC website:

New and improved multiple sclerosis (MS) drugs satisfying key unmet needs of oral administration and increased efficacy suggest a paradigm shift in MS therapy; ending the decade long dominance of interferon betas and Copaxone (glatiramer acetate, Teva) says independent analyst Datamonitor.

For more click here.